The SURMOUNT phase 3 trials evaluated tirzepatide versus placebo in people with obesity or overweight with at least 1 ...

Eli Lilly announced the latest results from the SURMOUNT-1 three-year study on the efficacy of tirzepatide in an Aug. 20 ...

The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.

When Lilly reported strong results from SURMOUNT-1 earlier this year, the drugmaker suggested it may be able to file for approval of tirzepatide in obesity before the end of this year. That won't ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...

353(b)(1)(D). So, at the threshold, the pharmacy would need to establish that i) it does not compound tirzepatide regularly or in inordinate amounts, and ii) its compounded tirzepatide is not ...

today announced the completion of its Phase 2 BMT-801 clinical study of the co-administration of MC4R bremelanotide + GLP-1/GIP tirzepatide for the treatment of obesity. The last patient enrolled ...